Glenmark has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Its Olanzapine for Injection is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Zyprexa IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253].

According to IQVIA sales data for the 12-month period ending May 2026, the Zyprexa IntraMuscular Injection market achieved annual sales of approximately USD 25.4 million.

Commenting on the launch, Marc Kikuchi, President and Business Head—North America, Glenmark, said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”